Purine Analogues: Rationale for Development, Mechanisms of Action, and Pharmacokinetics in Hairy Cell Leukemia

Hematology/Oncology Clinics of North America

Volumn 20, Issue 5, 2006, Pages 1087-1097

  Juliusson, Gunnar ^a,b   Liliemark, Jan ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE ARABINOSE; ALPHA INTERFERON; CLADRIBINE; FLUDARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW TOXICITY; BURST FORMING UNIT E; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLONY FORMING UNIT E; COLONY FORMING UNIT GM; COMBINED IMMUNODEFICIENCY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEVER; HAIRY CELL LEUKEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA CELL; LYMPHOMA; NEPHROTOXICITY; NEUROTOXICITY; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW;

ADENOSINE; ADENOSINE DEAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; DEOXYCYTIDINE KINASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, HAIRY CELL; NEOPLASM PROTEINS;

EID: 33748757243     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.06.007     Document Type: Review

References (45)

1. Hitchings G.H., Elion G.B., Falco E.A., et al. Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci 52 8 (1950) 1318-1335
2. Elion G.B., Hitchings G.H., and Vanderwerff H. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 192 2 (1951) 505-518
3. Walwick E., Decker C., and Roberts W. Cyclization during phosphorylation of uridine and cytidine. A new role to the O2 2′ cyclo nucleoside. Proc Chem Soc 53 (1959) 84
4. Dixon R.L., and Adamson R.H. Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemother Rep 48 (1965) 11-16
5. Montgomery J.A., and Hewson K. Synthesis of potential anticancer agents. XX. 2-Fluoropurines. J Am Chem Soc 82 (1960) 463-468
6. Montgomery J.A., and Hewson K. Nucleosides of 2-fluoroadenine. J Med Chem 12 3 (1969) 498-504
7. Christensen L.F., Broom A.D., Robins M.J., et al. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl) purines. J Med Chem 15 7 (1972) 735-739
8. Giblett E.R., Anderson J.E., Cohen F., et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2 7786 (1972) 1067-1069
9. Carson D.A., Kaye J., Matsumoto S., et al. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A 76 5 (1979) 2430-2433
10. Carson D.A., Wasson D.B., Taetle R., et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62 4 (1983) 737-743
11. Carson D.A., Wasson D.B., and Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci U S A 81 7 (1984) 2232-2236
12. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340 8825 (1992) 952-956
13. Petzer A.L., Bilgeri R., Zilian U., et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 78 10 (1991) 2583-2587
14. Piro L.D., Carrera C.J., Carson D.A., et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322 16 (1990) 1117-1121
15. Spiers A.S., Parekh S.J., and Bishop M.B. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 2 12 (1984) 1336-1342
16. Quesada J.R., Reuben J., Manning J.T., et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310 1 (1984) 15-18
17. Kantarjian H.M., Schachner J., and Keating M.J. Fludarabine therapy in hairy cell leukemia. Cancer 67 5 (1991) 1291-1293
18. Seto S., Carrera C.J., Kubota M., et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75 2 (1985) 377-383
19. Lechleitner M., Auer B., Zilian U., et al. The immunosuppressive substance 2-chloro-2-deoxyadenosine modulates lipoprotein metabolism in a murine macrophage cell line (P388 cells). Lipids 29 9 (1994) 627-633
20. Pettitt A.R., Clarke A.R., Cawley J.C., et al. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 105 4 (1999) 986-988
21. Pettitt A.R. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol 121 5 (2003) 692-702
22. Fenaux P., Preudhomme C., Lai J.L., et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 6 4 (1992) 246-250
23. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 6 (1995) 1580-1589
24. Valganon M., Giraldo P., Agirre X., et al. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 129 1 (2005) 53-59
25. Nahi H., Lehmann S., Mollgard L., et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 127 3 (2004) 285-291
26. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 9 (2001) 2777-2783
27. Bueso-Ramos C.E., Ferrajoli A., Medeiros L.J., et al. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology (Am Soc Hematol Educ Program) 9 4 (2004) 279-286
28. Sala R., Mauro F.R., Bellucci R., et al. Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. Eur J Haematol 61 1 (1998) 14-20
29. Liliemark J., Pettersson B., and Juliusson G. Determination of 2-chloro-2′-deoxyadenosine in human plasma. Biomed Chromatogr 5 6 (1991) 262-264
30. Liliemark J., and Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1 4 (1995) 385-390
31. Liliemark J., Albertioni F., Hassan M., et al. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10 10 (1992) 1514-1518
32. Lindemalm S., Liliemark J., Juliusson G., et al. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 210 2 (2004) 171-177
33. Saven A., Cheung W.K., Smith I., et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 14 3 (1996) 978-983
34. Albertioni F., Juliusson G., and Liliemark J. On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 44 6 (1993) 579-582
35. Juliusson G., Heldal D., Hippe E., et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13 4 (1995) 989-995
36. Liliemark J., and Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Blood 80 Suppl 1 (1992) 471a
37. Juliusson G., Lenkei R., and Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83 12 (1994) 3672-3681
38. Juliusson G., Lenkei R., Tjonnfjord G., et al. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor. Ann Oncol 6 4 (1995) 371-375
39. Juliusson G., Lenkei R., Tjonnfjord G., et al. Low-dose cladribine for symptomatic hairy cell leukaemia. Br J Haematol 89 3 (1995) 637-639
40. Santana V.M., Hurwitz C.A., Blakley R.L., et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84 4 (1994) 1237-1242
41. Krance R.A., Hurwitz C.A., Head D.R., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19 11 (2001) 2804-2811
42. Rubnitz J.E., Razzouk B.I., Srivastava D.K., et al. Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leuk Res 28 4 (2004) 349-352
43. Boogaerts M.A., Van Hoof A., Catovsky D., et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 19 22 (2001) 4252-4258
44. Juliusson G., Christiansen I., Hansen M.M., et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14 7 (1996) 2160-2166
45. Karlsson K., Stromberg M., Liliemark J., et al. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients. Br J Haematol 116 3 (2002) 538-548